Department of Thoracic Medicine, Royal Adelaide Hospital, Adelaide, SA, Australia.
Clin Exp Immunol. 2010 Sep;161(3):584-90. doi: 10.1111/j.1365-2249.2010.04186.x.
Immunosuppression therapy following lung transplant fails to prevent chronic rejection/bronchiolitis obliterans syndrome, which we have shown is associated with lack of suppression of peripheral blood T cell granzyme B, interferon (IFN)-γ and tumour necrosis factor (TNF)-α. We hypothesized that these proinflammatory mediators may increase with time post-transplant in otherwise stable patients before clinical signs of declining lung function, and patients experiencing declining lung function would show a further increase in these mediators. Intracellular cytokine profiles and granzyme B were investigated in T cells in whole blood and airways from lung transplant patients using flow cytometry. There was a significant negative correlation between forced expiratory volume in 1 s (FEV(1) ), drug dose and time post-transplant. A significant correlation between increased granzyme B, IFN-γ, interleukin (IL)-2 and TNF-α and time post-transplant was noted in peripheral blood T cells but not lung T cells from stable patients. Patients with similar drug dose but experiencing declining FEV(1) showed a further increase in peripheral blood T cell IFN-γ, IL-2 and TNF-α. Time post-lung transplant correlates with increasing peripheral blood T cell granzyme B and proinflammatory cytokines. Declining FEV(1) is associated with a further increase in these proinflammatory mediators. Drugs that reduce these inflammatory mediators effectively may reduce the incidence of chronic graft rejection.
肺移植后免疫抑制治疗未能预防慢性排斥反应/闭塞性细支气管炎综合征,我们已经表明,这与外周血 T 细胞颗粒酶 B、干扰素(IFN)-γ 和肿瘤坏死因子(TNF)-α抑制不足有关。我们假设,在其他稳定患者出现肺功能下降的临床迹象之前,这些促炎介质可能会随着移植后时间的推移而增加,而肺功能下降的患者会进一步增加这些介质。使用流式细胞术检测肺移植患者全血和气道中的 T 细胞细胞内细胞因子谱和颗粒酶 B。用力呼气量(FEV1)、药物剂量和移植后时间呈显著负相关。稳定患者外周血 T 细胞中颗粒酶 B、IFN-γ、白细胞介素(IL)-2 和 TNF-α与移植后时间呈显著正相关,但肺 T 细胞中无相关性。药物剂量相似但 FEV1 下降的患者外周血 T 细胞 IFN-γ、IL-2 和 TNF-α进一步增加。肺移植后时间与外周血 T 细胞颗粒酶 B和促炎细胞因子的增加相关。FEV1 的下降与这些促炎介质的进一步增加有关。减少这些炎症介质的药物可能会降低慢性移植物排斥反应的发生率。